Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 12, Pages 2573
Publisher
MDPI AG
Online
2020-12-02
DOI
10.3390/cells9122573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma
- (2020) Eun-Jin Yun et al. Cell Death & Disease
- Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
- (2019) Paul Lesueur et al. BMC CANCER
- Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
- (2019) Graham MacLeod et al. Cell Reports
- Nrf2 in cancers: A double‐edged sword
- (2019) Shijia Wu et al. Cancer Medicine
- DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
- (2019) Bernd Kaina et al. DNA REPAIR
- ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation
- (2019) Luciana Rodrigues Gomes et al. Cell Death & Disease
- Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma
- (2019) Kai Huang et al. Advanced Science
- Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma
- (2019) Petri Pölönen et al. ONCOGENE
- Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy
- (2019) Vivek Singh Tomar et al. CELL BIOLOGY AND TOXICOLOGY
- The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration Pathology
- (2019) Hyttinen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells
- (2019) Matheus Molina Silva et al. Scientific Reports
- HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway
- (2018) Wei Yang et al. CANCER LETTERS
- A highlight on Sonic hedgehog pathway
- (2018) Gabriela Basile Carballo et al. Cell Communication and Signaling
- Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
- (2018) Xiao-Tang Kong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Current state of immunotherapy for glioblastoma
- (2018) Michael Lim et al. Nature Reviews Clinical Oncology
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide
- (2018) Jilian R. Melamed et al. Oncotarget
- CRISPR/Cas9 library screening for drug target discovery
- (2017) Morito Kurata et al. JOURNAL OF HUMAN GENETICS
- Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
- (2017) Zhongling Zhu et al. JOURNAL OF NEUROCHEMISTRY
- High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells
- (2017) Patrícia Benites Gonçalves da Silva et al. Oncotarget
- Transcriptional Regulation by Nrf2
- (2017) Claudia Tonelli et al. ANTIOXIDANTS & REDOX SIGNALING
- Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes
- (2016) Marta Pajares et al. Autophagy
- Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
- (2016) Claudius Klein et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line
- (2016) Guo-zhong Yi et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Cornerstones of CRISPR–Cas in drug discovery and therapy
- (2016) Christof Fellmann et al. NATURE REVIEWS DRUG DISCOVERY
- Wnt signaling in cancer
- (2016) T Zhan et al. ONCOGENE
- NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
- (2016) Clarissa Ribeiro Reily Rocha et al. Oncotarget
- Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
- (2015) J. L. McFaline-Figueroa et al. CANCER RESEARCH
- p62 links autophagy and Nrf2 signaling
- (2015) Tao Jiang et al. FREE RADICAL BIOLOGY AND MEDICINE
- Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
- (2015) Silvana Konermann et al. NATURE
- Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
- (2015) Malin Wickström et al. Nature Communications
- The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis
- (2014) V. Pekovic-Vaughan et al. GENES & DEVELOPMENT
- Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle
- (2014) Céline Feillet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
- (2014) C R R Rocha et al. Cell Death & Disease
- Role of Nrf2 in Oxidative Stress and Toxicity
- (2013) Qiang Ma Annual Review of Pharmacology and Toxicology
- The emerging role of the Nrf2-Keap1 signaling pathway in cancer
- (2013) M. C. Jaramillo et al. GENES & DEVELOPMENT
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion
- (2012) Yasushi Sasaki et al. CANCER BIOLOGY & THERAPY
- Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
- (2012) Tor-Christian Aase Johannessen et al. Expert Review of Anticancer Therapy
- Gene Overexpression: Uses, Mechanisms, and Interpretation
- (2012) G. Prelich GENETICS
- Unknown
- (2011) Ilya Ulasov et al. MOLECULAR MEDICINE
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) R. Stupp et al. ANNALS OF ONCOLOGY
- hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation
- (2009) V. Walia et al. CANCER RESEARCH
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- (2009) Aimee L. Jackson et al. NATURE REVIEWS DRUG DISCOVERY
- Circadian oscillation of nucleotide excision repair in mammalian brain
- (2009) Tae-Hong Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More